Updated Data from LEGEND-2, a Phase 1/2 Open-label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Long-term Responses, Safety Profile, and Complete Response Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myelomama
Updated Data from LEGEND-2, a Phase 1/2 Open-label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Long-term Responses, Safety Profile, and Complete Response Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myelomama
Dec 9, 2019
